“
TL;DR
The central result is the highlighting of CHI3L1's role as a key regulatory factor and potential therapeutic target, particularly in enhancing the efficacy of immune checkpoint blockade.
International Journal of Molecular Sciences · 3 authors, 1 centre
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central result is the highlighting of CHI3L1's role as a key regulatory factor and potential therapeutic target, particularly in enhancing the efficacy of immune checkpoint blockade.
It is reported to be significantly elevated in various conditions, including liver fibrosis, endometrial cancer, asthma, and other cancers and inflammatory diseases. The review discusses CHI3L1's association with immune checkpoints, noting its positive correlation with PD-L1 expression and that blocking it may enhance the efficacy of anti-PD-L1 therapy in preclinical models. Limitations include that most supporting research is concentrated on mouse models, and the complexity of disease mechanisms necessitates further investigation.